Full Description
CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. Chapters in this release include Current approaches in CRISPR -Cas systems for metabolic disorders, Recent progress in CRISPR -Cas systems for CRISPR for retinal diseases, Recent progress in CRISPR -Cas systems for cataract and blindness, Advances in CRISPR -Cas systems for muscular dystrophy, Recent development in CRISPR -Cas systems for cardiac disease, Current approaches in CRISPR -Cas systems for diabetes, and much more.
Additional sections cover Advances in CRISPR -Cas systems for liver disease, Advances in CRISPR -Cas systems for lung disease, Advances in CRISPR -Cas systems for kidney diseases, Current progress in CRISPR -Cas systems for rare disease, Advances in CRISPR -Cas systems for heredity disease, Recent progress in CRISPR -Cas systems for neurological disorders, and CRISPR challenges in clinical developments.
Contents
Preface
Vijai Singh
1. Current approaches in CRISPR -Cas systems for metabolic disorders
DHRUV KUMAR
2. Recent progress in CRISPR -Cas systems for CRISPR for retinal diseases
Mayank Bansal
3. Recent progress in CRISPR -Cas systems for cataract and blindness
Suresh Ramakrishna
4. Advances in CRISPR -Cas systems for muscular dystrophy
Vancha Harish
5. Recent development in CRISPR -Cas systems for cardiac disease
Xin Wang
6. Current approaches in CRISPR -Cas systems for diabetes
L. Karthik
7. Advances in CRISPR -Cas systems for liver disease
Majid Mojarrad
8. Advances in CRISPR -Cas systems for lung disease
Suresh Ramakrishna
9. Advances in CRISPR -Cas systems for kidney diseases
Anil Bhanudas Gaikwad
10. Current progress in CRISPR -Cas systems for rare disease
Ajay Kumar I
11. Advances in CRISPR -Cas systems for heredity disease
DHRUV KUMAR
12. Recent progress in CRISPR -Cas systems for neurological disorders
Anand Krishna Tiwari
13. CRISPR challenges in clinical developments
Hossein Soltaninejad, Mohadeseh Khoshandam and Saman Hosseinkhani
